Anebulo Pharmaceuticals, Inc. SEC filings ANEB
Anebulo Pharmaceuticals, Inc. has 204 filings in SEC EDGAR's recent list, going back to Jun 25, 2020. Its latest annual report, Form 10-K, was filed on Sep 29, 2025 for the period ended Jun 30, 2025. The latest quarterly report (Form 10-Q) was filed on Feb 12, 2026, covering the quarter ended Dec 31, 2025. The most recent current report (Form 8-K) was filed on Feb 12, 2026 (results of operations). The company's fiscal year ends on June 30.
| Form | Description | Filed | Period |
|---|---|---|---|
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 13, 2026 | — |
| SC 13E3/A | Sc to-i/a | Jan 29, 2026 | — |
| SC 13E3/A | Sc to-i/a | Jan 27, 2026 | — |
| SC 13E3/A | Sc to-i/a | Jan 8, 2026 | — |
| SC 13E3 | Sc to-i | Dec 22, 2025 | — |
| SC 13E3/A | Filing | Oct 14, 2025 | — |
| SC 13E3/A | Filing | Sep 15, 2025 | — |
| SC 13E3 | Filing | Jul 23, 2025 | — |
| 4 | Insider transaction | Apr 7, 2025 | Apr 4, 2025 |
| 4 | Insider transaction | Apr 7, 2025 | Apr 4, 2025 |
| 4 | Insider transaction | Apr 7, 2025 | Apr 4, 2025 |
| 4 | Insider transaction | Apr 7, 2025 | Apr 4, 2025 |
| 4 | Insider transaction | Apr 7, 2025 | Apr 4, 2025 |
| 4 | Insider transaction | Apr 7, 2025 | Apr 4, 2025 |
| 4 | Insider transaction | Apr 7, 2025 | Apr 4, 2025 |
| 4 | Insider transaction | Apr 7, 2025 | Apr 4, 2025 |
| 4 | Insider transaction | Apr 7, 2025 | Apr 4, 2025 |
| SCHEDULE 13G | Ownership over 5% (passive) | Mar 17, 2025 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Feb 27, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Feb 14, 2025 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Dec 26, 2024 | — |
| 4 | Insider transaction | Dec 26, 2024 | Dec 23, 2024 |
| 4 | Insider transaction | Dec 10, 2024 | Dec 9, 2024 |
| 4 | Insider transaction | Jun 17, 2024 | Jun 13, 2024 |
| 4 | Insider transaction | Jun 17, 2024 | Jun 13, 2024 |
| 4 | Insider transaction | Jun 17, 2024 | Jun 13, 2024 |
| 4 | Insider transaction | Jun 17, 2024 | Jun 13, 2024 |
| 4 | Insider transaction | Jun 17, 2024 | Jun 13, 2024 |
| 4 | Insider transaction | Jun 17, 2024 | Jun 13, 2024 |
| 4 | Insider transaction | Jun 17, 2024 | Jun 13, 2024 |
| 4/A | Filing | Mar 8, 2024 | Feb 29, 2024 |
| 4 | Insider transaction | Mar 1, 2024 | Feb 29, 2024 |
| 4 | Insider transaction | Dec 20, 2023 | Nov 13, 2023 |
| 4 | Insider transaction | Oct 11, 2023 | Oct 6, 2023 |
| 3 | Initial insider ownership | Oct 11, 2023 | Oct 6, 2023 |
| 4 | Insider transaction | Oct 10, 2023 | Oct 6, 2023 |
| 3 | Initial insider ownership | Oct 10, 2023 | Oct 6, 2023 |
| 3 | Initial insider ownership | Oct 2, 2023 | Sep 28, 2023 |
| 3 | Initial insider ownership | Apr 4, 2023 | Mar 2, 2023 |
| 4 | Insider transaction | Dec 13, 2022 | Dec 9, 2022 |
| 4 | Insider transaction | Dec 13, 2022 | Dec 9, 2022 |
| 4 | Insider transaction | Nov 2, 2022 | Nov 1, 2022 |
| 3 | Initial insider ownership | Nov 2, 2022 | Oct 28, 2022 |
| 4 | Insider transaction | Oct 4, 2022 | Apr 21, 2022 |
| 4 | Insider transaction | Oct 4, 2022 | Apr 21, 2022 |
| 4 | Insider transaction | Oct 3, 2022 | Apr 21, 2022 |
| 4 | Insider transaction | Oct 3, 2022 | Apr 21, 2022 |
| 4 | Insider transaction | Oct 3, 2022 | Apr 21, 2022 |
| 4 | Insider transaction | Oct 3, 2022 | Jun 27, 2022 |
| 4 | Insider transaction | Sep 30, 2022 | Apr 21, 2022 |
| 4 | Insider transaction | Jun 7, 2022 | Jun 1, 2022 |
| 3 | Initial insider ownership | May 24, 2022 | May 20, 2022 |
| 4 | Insider transaction | Feb 7, 2022 | Feb 7, 2022 |
| 3 | Initial insider ownership | Feb 7, 2022 | Feb 1, 2022 |
| 4 | Insider transaction | Dec 21, 2021 | Dec 17, 2021 |
| 4 | Insider transaction | Dec 16, 2021 | Dec 14, 2021 |
| 4 | Insider transaction | Dec 3, 2021 | Dec 3, 2021 |
| 4 | Insider transaction | Dec 3, 2021 | Dec 2, 2021 |
| 4/A | Filing | May 17, 2021 | May 6, 2021 |
| SC 13D | Ownership over 5% (active) | May 17, 2021 | — |
| 4 | Insider transaction | May 7, 2021 | May 6, 2021 |
| 3 | Initial insider ownership | May 6, 2021 | May 6, 2021 |
| 3 | Initial insider ownership | May 6, 2021 | May 6, 2021 |
| 3 | Initial insider ownership | May 6, 2021 | May 6, 2021 |
| 3 | Initial insider ownership | May 6, 2021 | May 6, 2021 |
| 3 | Initial insider ownership | May 6, 2021 | May 6, 2021 |
| 3 | Initial insider ownership | May 6, 2021 | May 6, 2021 |
| 3 | Initial insider ownership | May 6, 2021 | May 6, 2021 |
| 3 | Initial insider ownership | May 6, 2021 | May 6, 2021 |
Showing 69 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ANEB (OTC)
- Fiscal year ends
- June 30
- Incorporated in
- DE
- Headquarters
- Lakeway, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1815974
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.